Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

Progress in the colorectal and lung cancer study; partner starts HIV study with lead product MGN1703Cash inflow of € 28.3 million following capital increaseForecast for 2015 financial year confirmedDr. Mariola Söhngen appointed as new Chief Executive Officer (CEO); further changes in Executive BoardOliver Krautscheid re-elected as member and... [more]

MOLOGEN AG announces that the United States Patent and Trademark Office (PTO) has declared that it will grant a patent (Notice of Allowance) for the combined use of the lead product, immunotherapy MGN1703, with a chemotherapeutic agent. [more]

Interim Report 2nd Quarter 2015

Download PDF (0,4 MB)

Interim Report 1st Quarter 2015

Download PDF (0,4 MB)

Annual Report 2014

Download PDF (0,4 MB)